Press Releases :: iBio Inc. (IBIO)

Skip to main content Skip to section navigation Skip to footer

Year

Category

May 4, 2021 5:00 pm EDT

iBio and Fraunhofer USA Conclude Litigation and Enter License Agreement

Mar 9, 2021 4:30 pm EST

iBio to Participate in the 33rd Annual Roth Conference

Feb 16, 2021 4:05 pm EST

iBio Reports Fiscal Second Quarter 2021 Financial Results and Provides Corporate Update

Feb 16, 2021 8:00 am EST

iBio Appoints Robert M. Lutz as Chief Financial & Business Officer

Feb 9, 2021 4:30 pm EST

iBio to Report Fiscal 2021 Second Quarter Financial Results and Provide Corporate Update on Tuesday, February 16, 2021

Dec 28, 2020 7:30 am EST

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

Dec 10, 2020 4:30 pm EST

iBio Announces Closing of its Public Offering of Common Stock

Dec 8, 2020 8:55 am EST

iBio Announces Pricing of $35 Million Public Offering of Common Stock

Dec 7, 2020 4:01 pm EST

iBio Announces Proposed Public Offering of Common Stock

Dec 1, 2020 4:30 pm EST

iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins